Sandoz Is ‘Not Aiming To Be A Leader’ In US Small-Molecule Generics
North America Chief Keren Haruvi Admits Firm Is ‘Still Suffering’ From Aborted Divestment
Executive Summary
In a frank acknowledgement of Sandoz’s position in the US small-molecule generics market, the company’s North America president Keren Haruvi has indicated that the firm is “not looking to be a leader in the generics space” and is still suffering from a lack of investment made in its pipeline during the period several years ago when it was looking to sell the oral solids business.